Peptide Monograph

IGF-1 LR3

Long R3 Insulin-Like Growth Factor 1

At a Glance

Mechanism of Action

IGF-1 LR3 (Long R3 Insulin-Like Growth Factor 1) is a modified form of the naturally occurring 70-amino-acid protein insulin-like growth factor 1 (IGF-1). The native IGF-1 protein was first characterized by Rinderknecht and Humbel in 1978 as a somatomedin with structural homology to proinsulin, and plays a central role in mediating growth hormone (GH) effects on tissue growth, metabolism, and cell survival.[1]

IGF-1 LR3 incorporates two critical modifications to the native IGF-1 sequence: a substitution of glutamic acid (Glu) for arginine (Arg) at position 3 (the "R3" designation), and a 13-amino-acid N-terminal extension peptide (the "Long" designation). These modifications were engineered by Francis et al. to dramatically reduce the binding affinity of the molecule for IGF-binding proteins (IGFBPs), the family of six serum proteins that normally sequester and regulate the bioavailability of circulating IGF-1.[2]

In normal physiology, over 99% of circulating IGF-1 is bound to IGFBPs (primarily IGFBP-3 in a ternary complex with acid-labile subunit), which limits free IGF-1 availability and extends its half-life to approximately 12–15 hours in the bound state. Free, unbound native IGF-1 has a half-life of only approximately 12–15 minutes. Because IGF-1 LR3 has greatly reduced IGFBP binding, it circulates predominantly in the free, bioactive form, resulting in a functional half-life of approximately 20–30 hours and substantially increased bioavailability compared to native IGF-1.[2][3]

IGF-1 LR3 retains full binding affinity for the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase expressed on virtually all cell types. Upon binding IGF-1R, the receptor undergoes autophosphorylation and activates two primary intracellular signaling cascades:

• PI3K/Akt pathway — Promotes protein synthesis via mTOR activation, inhibits apoptosis (cell death) via phosphorylation of BAD and caspase-9, and stimulates glucose uptake. This pathway is the principal mediator of IGF-1's anabolic and anti-apoptotic effects.
• Ras/MAPK/ERK pathway — Drives cell proliferation, differentiation, and mitogenic signaling. This pathway is critical for IGF-1's growth-promoting effects across tissues.

The net biological effect is potent stimulation of muscle hypertrophy (increased protein synthesis and reduced proteolysis), muscle hyperplasia (increased cell number, demonstrated in animal models), and systemic anabolic signaling. IGF-1 LR3 also exhibits significant insulin-like metabolic activity, including glucose uptake stimulation and lipogenesis, which accounts for the clinically significant hypoglycemia risk associated with its use.[3][4]

Evidence Summary

Biochemical Characterization

Francis et al. comprehensively characterized IGF-1 LR3's binding properties, demonstrating that the dual modification (R3 substitution + N-terminal extension) reduces IGFBP binding affinity by approximately 100-fold while preserving full IGF-1R activation. This work established IGF-1 LR3 as a research tool for studying IGF-1 signaling without the confound of IGFBP sequestration, and it rapidly became the standard IGF-1 supplement for mammalian cell culture due to its enhanced potency and stability in serum-containing media.[2]

Cell Culture and In Vitro Research

IGF-1 LR3 is one of the most widely used growth factors in cell biology research. It is routinely included in serum-free and reduced-serum cell culture media for its ability to promote cell proliferation and survival at low concentrations (typically 20–100 ng/mL). Its resistance to IGFBP sequestration makes it approximately 2–3 times more potent than native IGF-1 in most cell culture applications.[2]

Native IGF-1 Clinical Evidence (Mecasermin)

The FDA approved mecasermin (Increlex), recombinant human IGF-1, in 2005 for the treatment of severe primary IGF-1 deficiency (primary IGFD) in children with growth failure. Clinical trials conducted by Laron, Rosenfeld, and others demonstrated significant linear growth acceleration in children with Laron syndrome (GH receptor deficiency) and other forms of primary IGFD. These trials also established the side effect profile of exogenous IGF-1 administration, including significant hypoglycemia risk, which is expected to be amplified with IGF-1 LR3 due to its greater bioavailability.[4][5]

Animal Studies

Animal studies with native IGF-1 and IGF-1 analogs have demonstrated increased lean body mass, muscle hypertrophy, and in some models muscle hyperplasia (increased fiber number). Long-term IGF-1 overexpression studies in transgenic animals have also demonstrated dose-dependent organ enlargement (organomegaly) and, in some models, increased tumor susceptibility, underscoring the importance of the growth-promoting pathway in oncogenesis.[3]

Primary Uses (in Research)

Based on the available biochemical characterization and extrapolation from native IGF-1 literature, IGF-1 LR3 has been investigated or used for the following applications:

• Cell culture supplement — The primary legitimate research use. IGF-1 LR3 is the industry-standard IGF-1 form for promoting cell proliferation and survival in mammalian cell culture systems, due to its resistance to IGFBP sequestration and extended stability.[2]
• Muscle hypertrophy research — IGF-1 signaling through the PI3K/Akt/mTOR pathway is a well-established driver of muscle protein synthesis. Native IGF-1 studies demonstrate dose-dependent increases in muscle mass in animal models. IGF-1 LR3's enhanced bioavailability makes it a subject of interest in anabolic research contexts.[3]
• Muscle hyperplasia investigation — Unlike most anabolic agents that increase muscle fiber size (hypertrophy), IGF-1 signaling has been associated with satellite cell activation and new fiber formation (hyperplasia) in preclinical models, representing a qualitatively different mechanism of muscle growth.
• Anti-catabolic / recovery applications — IGF-1's potent anti-apoptotic signaling (via Akt-mediated inhibition of BAD and caspase-9) suggests applications in reducing muscle wasting and promoting tissue recovery, though this has not been validated for IGF-1 LR3 specifically.
• Growth factor signaling research — As a tool compound for studying IGF-1R signaling independent of IGFBP modulation, IGF-1 LR3 has contributed to understanding of the GH/IGF-1 axis, insulin signaling crosstalk, and growth factor biology.[2]

Contraindications

Standard Protocols

Cycling (typically 4 weeks on, 4 weeks off) is commonly recommended in research protocols due to concerns about IGF-1 receptor desensitization and the potential for prolonged exposure to promote unwanted tissue growth. Administration is often timed around training sessions, with some protocols specifying post-workout injection to align with the natural post-exercise elevation in IGF-1 signaling.

Due to the significant hypoglycemia risk, it is critical to administer IGF-1 LR3 with adequate carbohydrate intake. Some protocols recommend consuming a meal containing 30–50 g of carbohydrates within 15–30 minutes of injection.

Common Stacks & Synergies

IGF-1 LR3 is frequently combined with other compounds in self-experimentation protocols. The following combinations are commonly reported but lack published clinical evidence supporting their combined use:

• IGF-1 LR3 + GH (growth hormone) — The most commonly discussed combination. The rationale is that exogenous GH raises endogenous IGF-1 levels via hepatic production, while IGF-1 LR3 provides direct IGF-1R activation that bypasses IGFBP regulation. The combination is theorized to produce synergistic anabolic effects, though the additive hypoglycemia and growth-promoting risks are significant.
• IGF-1 LR3 + GH Secretagogues (CJC-1295/Ipamorelin) — Some protocols substitute GH secretagogues for exogenous GH, theorizing a more physiological GH pulsatility combined with the direct IGF-1R activation of LR3.
• IGF-1 LR3 + Insulin — An extremely high-risk combination reported in bodybuilding contexts. The combined insulin-like metabolic effects create severe hypoglycemia risk. This combination is explicitly discouraged due to potentially life-threatening hypoglycemic episodes.
• IGF-1 LR3 + MGF (Mechano Growth Factor) — The proposed rationale is that MGF activates satellite cells (proliferation) while IGF-1 LR3 promotes their subsequent differentiation and fusion. The theoretical basis is sound but unvalidated in controlled studies.

Preparation & Administration

IGF-1 LR3 is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 100 mcg or 1 mg of peptide. It must be reconstituted before injection.

Reconstitution

IGF-1 LR3 should be reconstituted with bacteriostatic water (BAC water) or 0.6% acetic acid solution. Some manufacturers recommend acetic acid reconstitution for improved stability. For a 1 mg vial reconstituted with 1 mL of BAC water, each 0.1 mL (10 units on a standard insulin syringe) delivers 100 mcg. For a 50 mcg dose, draw 0.05 mL (5 units). For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

IGF-1 LR3 is typically administered via subcutaneous injection in the abdominal area. Some protocols employ intramuscular injection into specific target muscles post-workout, based on the theory that local IGF-1R activation may preferentially promote hypertrophy in the injected muscle, though systemic distribution occurs regardless of injection site. Use a 29–31 gauge insulin syringe. Rotate injection sites between administrations. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Dosing Precision

Because IGF-1 LR3 is dosed in micrograms (not milligrams like TB-500 or BPC-157), precise reconstitution volume calculations are critical. Small errors in reconstitution can result in significant dosing inaccuracies. Use of a calibrated insulin syringe with clear unit markings is essential. For concentration calculations, see the Reconstitution Calculator.

Side Effects & Adverse Events

Extrapolated from mecasermin (native IGF-1) clinical experience:

• Hypoglycemia — The most significant acute risk. Mecasermin carries an FDA black box warning for hypoglycemia. IGF-1 LR3's enhanced bioavailability and prolonged half-life may result in more severe and prolonged hypoglycemic episodes than native IGF-1. Symptoms include dizziness, sweating, tremor, confusion, and in severe cases, seizure or loss of consciousness.[5]
• Joint pain and swelling — Commonly reported with mecasermin therapy. IGF-1 promotes growth of connective tissue including cartilage and synovium.
• Edema (fluid retention) — IGF-1 promotes renal sodium retention. Peripheral edema is a recognized side effect of mecasermin.
• Jaw and hand growth (acromegalic features) — With chronic use, sustained IGF-1R activation can promote growth of acral tissues (hands, feet, jaw), mimicking acromegaly. This risk increases with dose and duration of use.
• Organ enlargement (organomegaly) — IGF-1 promotes growth of internal organs including the heart, kidneys, and spleen. Cardiomegaly is a particular concern with chronic use due to potential cardiac functional consequences.
• Injection site reactions — Pain, redness, or lipohypertrophy at injection sites.

Self-reported side effects from community use (unverified):

• Hypoglycemia symptoms (most commonly reported, often within 30–60 minutes of injection)
• Lethargy and fatigue
• Headache
• Gut distension with chronic high-dose use ("GH gut" / visceral growth)
• Numbness or tingling in extremities

Drug Interactions

No formal drug interaction studies have been conducted with IGF-1 LR3. The following interactions are based on the known pharmacology of IGF-1 and clinical experience with mecasermin:

• Insulin and insulin secretagogues (sulfonylureas, meglitinides) — Additive hypoglycemia risk. IGF-1's insulin-like metabolic activity combined with exogenous insulin or insulin secretagogues can produce severe, potentially life-threatening hypoglycemia. Dose adjustment of diabetic medications may be necessary.[5]
• Growth hormone (GH) — Combined use increases total IGF-1 signaling and amplifies both anabolic effects and adverse effects (hypoglycemia, edema, tissue growth). Mecasermin prescribing information recommends against concurrent GH therapy.
• Anti-cancer therapies (particularly IGF-1R inhibitors) — IGF-1 LR3 would directly antagonize IGF-1R-targeted cancer therapies. Concurrent use with any cancer therapy should be avoided.
• Corticosteroids — Chronic corticosteroid use suppresses the GH/IGF-1 axis. The interaction with exogenous IGF-1 LR3 is complex and unpredictable.
• Anticoagulants — IGF-1 has effects on vascular endothelium and platelet function. Theoretical interaction with anticoagulant therapy; clinical significance is unknown.

Storage & Handling

IGF-1 LR3 is a relatively large protein (83 amino acids) and is more susceptible to degradation than smaller peptides. Do not freeze reconstituted solution. Protect from prolonged light exposure and avoid vigorous shaking during reconstitution (swirl gently). If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Some manufacturers recommend reconstitution with 0.6% acetic acid for improved stability over bacteriostatic water.

Legal & Regulatory Status

• FDA (United States) — IGF-1 LR3 is not approved for any indication. It is sold under the research chemical designation "not for human consumption." Native recombinant human IGF-1 (mecasermin, brand name Increlex) is FDA-approved for treatment of severe primary IGF-1 deficiency in children with growth failure and is available only by prescription.[5]
• WADA (World Anti-Doping Agency) — IGF-1 and all its analogs (including IGF-1 LR3) are explicitly listed on the WADA Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). They are banned at all times (both in-competition and out-of-competition). Athletes subject to WADA testing must not use IGF-1 LR3.
• European Union — Not approved as a medicinal product. Available as a research chemical with varying regulatory status by member state.
• Australia (TGA) — Not approved. Classified as a prescription-only substance. Import for personal use requires a valid prescription.
• China — A major source of commercial IGF-1 LR3 production for the research chemical market. Regulatory oversight of peptide manufacturing quality varies significantly between suppliers.

Open Questions

Significant gaps exist in the IGF-1 LR3 evidence base. Key unresolved questions include:

• No human pharmacokinetic data — The half-life, bioavailability, clearance, and tissue distribution of IGF-1 LR3 in humans have never been formally characterized. The commonly cited 20–30 hour half-life is estimated from in vitro IGFBP binding data and animal pharmacokinetics, not human PK studies.
• Cancer risk with chronic use — Epidemiological data consistently associates elevated endogenous IGF-1 levels with increased cancer risk. Whether exogenous IGF-1 LR3 administration increases cancer incidence, and at what dose and duration, is an important and unanswered question.[3]
• Hyperplasia vs. hypertrophy in humans — The muscle hyperplasia (new fiber formation) attributed to IGF-1 signaling has been demonstrated in animal models but not confirmed in humans. Whether IGF-1 LR3 produces true hyperplasia in human skeletal muscle remains unproven.
• Organ growth reversibility — The degree to which IGF-1 LR3-induced organ enlargement (particularly cardiac) is reversible upon discontinuation is unknown.
• Product quality and consistency — As an unregulated research chemical, the purity, accurate peptide content, sterility, correct folding (critical for large proteins), and endotoxin levels of commercially available IGF-1 LR3 products cannot be guaranteed.
• Optimal cycling protocol — The commonly recommended 4-weeks-on/4-weeks-off cycling protocol has no empirical basis and has not been evaluated for efficacy or safety.

Bibliography

1. Rinderknecht E, Humbel RE. "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin." J Biol Chem. 1978;253(8):2769-76. PMID:632300.
2. Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. "Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency." J Mol Endocrinol. 1992;8(3):213-23. doi:10.1677/jme.0.0080213. PMID:1381175.
3. LeRoith D, Roberts CT Jr. "The insulin-like growth factor system and cancer." Cancer Lett. 2003;195(2):127-37. doi:10.1016/s0304-3835(03)00159-9. PMID:12767520.
4. Laron Z. "Insulin-like growth factor 1 (IGF-1): a growth hormone." Mol Pathol. 2001;54(5):311-6. doi:10.1136/mp.54.5.311. PMID:11577173.
5. Rosenfeld RG, Hwa V, Wilson L, Lopez-Bermejo A, Buckway C, Burren C, Chernausek SD, Gelato M, Goddard A, Guzman A, Polak M, Savage MO. "The insulin-like growth factor-I receptor and its ligands in fetal and neonatal growth." Endocr Dev. 2005;9:17-30. doi:10.1159/000085751. PMID:15879686.
6. Clemmons DR. "Role of IGF-I in skeletal muscle mass maintenance." Trends Endocrinol Metab. 2009;20(7):349-56. doi:10.1016/j.tem.2009.04.002. PMID:19729319.